As an OX40 antagonist, it blocks the signaling mediated by this receptor, preventing T-cell activation and proliferation, which in turn reduces the inflammatory cascade characteristic of diseases mediated by these cells, such as AD. Here, TNFRSF4 is linked to Alzheimer disease.